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Abstract
Currently available vaccines for the pandemic Influenza A (H1N1) 2009 produced in chicken eggs have serious
impediments viz limited availability, risk of allergic reactions and the possible selection of sub-populations differing
from the naturally occurring virus, whereas the cell culture derived vaccines are time consuming and may not
meet the demands of rapid global vaccination required to combat the present/future pandemic. Hemagglutinin
(HA) based subunit vaccine for H1N1 requires the HA protein in glycosylated form, which is impossible with the
commonly used bacterial expression platform. Additionally, bacterial derived protein requires extensive purification
and refolding steps for vaccine applications. For these reasons an alternative heterologous system for rapid, easy
and economical production of Hemagglutinin protein in its glycosylated form is required. The HA gene of novel
H1N1 A/California/04/2009 was engineered for expression in Pichia pastoris as a soluble secreted protein. The full
length HA- synthetic gene having a-secretory tag was integrated into P. pastoris genome through homologous
recombination. The resultant Pichia clones having multiple copy integrants of the transgene expressed full length
HA protein in the culture supernatant. The Recombinant yeast derived H1N1 HA protein elicited neutralising
antibodies both in mice and rabbits. The sera from immunised animals also exhibited Hemagglutination Inhibition
(HI) activity. Considering the safety, reliability and also economic potential of Pichia expression platform, our
preliminary data indicates the feasibility of using this system as an alternative for large-scale production of
recombinant influenza HA protein in the face of influenza pandemic threat.
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Background
Influenza viruses belonging to the Orthomyxoviridae
family are enveloped viruses with segmented negative
sense RNA genome surrounded by a helical symmetry
shell. The 2009 H1N1 novel virus derived its genes from
viruses circulating in the pig population [1-3]. Current
influenza vaccines protect against homologous viruses
but are less effective against antigenic variants and pro-
vide little protection against a different subtype. In the
event of a pandemic, existing vaccines may be ineffective
because the manufacturing process requires at least six
months from identification of the pandemic strain to
distribution which is insufficient time to prevent wide-
scale morbidity or mortality. New vaccine strategies are
therefore needed that can both accelerate production
and provide broader spectrum protection. In case of
Influenza virus, it is the HA surface glycoprotein that
mediates virus entry and is the most important target of
antibody-mediated protection [4]. Cellular proteases
cleave the HA precursor (HA0) into HA1 and HA2 sub-
units. The HA1 surface subunit mediates the binding to
cell surface sialic acid receptors and the HA2 transmem-
brane subunit mediates membrane fusion between viral
and endosomal membranes after endocytosis [5]. Both
during infection and vaccination, HA protein is known
to elicit neutralizing antibodies. From the HA antigenic
maps, it is evident that HA1 is the major target of neu-
tralizing antibodies that inhibit virus binding to target
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tion inhibition (HI) assay [6-8]. Hence recombinant HA
protein based subunit vaccines offer an alternative over
conventional vaccine strategies that could save several
months of manufacturing time, since the HA gene of
the newly circulating strain is available shortly after
virus isolation or nucleotide sequencing of HA gene. In
contrast to conventional approaches there is no need for
live influenza virus or large quantities of eggs, and subu-
nit vaccines could be deployed earlier in the pandemic
for effective reduction of morbidity and mortality. It is
also economical to produce these vaccines capable of
inducing antibody that can neutralize the circulating
strain of influenza. As it is very important to produce
the antigenic protein in its native soluble and glycosy-
lated form, prokaryotic system like bacteria may not be
suitable for making this vaccine protein. E.coli being
prokaryote is unable to correctly fold the foreign protein
and perform other post-translational modifications thus
limiting the types of protein(s) that can be expressed.
Since the protein product may be typically obtained as
insoluble, mis-folded inclusion bodies, subsequent solu-
bilization and re-folding steps are required [9,10]. This
incorrect folding can be a result of inadequate intracel-
lular chaperone concentrations or the reducing environ-
ment of the cytoplasm [11]. E. coli is therefore not
generally suitable for use in expression studies with pro-
teins that contain a high level of disulphide connectivity
or proteins that require other types of post-translational
modifications such as glycosylation [12,13]. E.coli
expressed proteins also tend to retain their amino-term-
inal methionine, which may affect protein stability as
reported earlier [14,15].
Previous studies on bacterially expressed HA proteins
of H5N1 avian influenza virus (AIV) have reported that
in the absence of glycosylation, the newly synthesized
HA proteins are not likely to fold properly or trimerize
like native HA molecules, and may not present native
conformational epitopes, which are important for gen-
eration of an effective protective immune response
[16-18]. Indeed majority of the previous studies did not
demonstrate proper folding and/or oligomerization of
the HA proteins produced in prokaryotic systems
[16-20]. The recombinant protein expressed in E.coli as
inclusion bodies, requires careful optimization of the re-
folding conditions [21-23]. Optimization of such re-fold-
ing conditions may be difficult to achieve and is also
time consuming [24-26]. In addition, this would also
result in significant losses of the recombinant protein,
lower productivities and increased costs of manufacture
of the expressed protein. Expression of HA in insect
cells and mammalian cells are under development and/
or clinical trials [27-29]. The main challenge to the
recombinant technology is to ensure that the HA
products resemble the native virion-associated trimeric
spike proteins and can elicit robust immune responses
targeting protective conformational epitopes of HA.
Yeast (Pichia pastoris) has emerged as an ideal organ-
ism to express viral antigens because yeast glycosylate
proteins more similarly to mammals than bacteria.
Compared with insect or mammalian cells, expression
of recombinant proteins in yeast could present a viable
alternative in terms of large scale vaccine production
a n das h o r tt i m el i n es u i t a b l ef o rr a p i dr e s p o n s ei n
influenza pandemic. Pichia pastoris is methylotrophic
yeast, capable of metabolizing methanol as its sole car-
bon source. It can metabolise methanol using the
enzyme alcohol oxidase during oxidation that take place
in peroxisomes. The formaldehyde and hydrogen perox-
ide formed are sequestered within the peroxisomes.
Alcohol oxidase has a poor affinity for oxygen and
Pichia pastoris compensates by generating large
amounts of the enzyme. Hence the promoter regulating
the production of alcohol oxidase is widely used to drive
heterologous protein expression in Pichia. Multiple copy
integration of recombinant genes in Pichia has been
demonstrated to increase expression of the desired pro-
tein in many cases [30-36]. More recently, P. pastoris
has been used to express therapeutic proteins that have
entered clinical trials [37]. Further development in the
field of therapeutic glycoprotein production with P.pas-
toris strains is expected due to recent advances in
genetic engineering of human glycosylation pathways
into yeasts [38-40]. With the ability to replicate certain
human glycosylation patterns, yeast-based expression
platforms offer an attractive alternative to current mam-
malian or insect cell culture processes due to a variety
of additional advantages viz cheaper operating costs,
simple chemically defined media and no viral contami-
n a t i o n .I nl i g h to ft h ea b o v ef a c t s ,w eh a v ei n v e s t i g a t e d
t h ef e a s i b i l i t yo fu s i n gPichia pastoris as an expression
host for recombinant production of H1N1 HA protein
and elicitation of neutralising antibodies against the
same protein in BALB/c mice and rabbits.
Results
Generation of recombinant Pichia pastoris with multi copy
integrants of H1N1 HA gene
Full length H1N1 HA synthetic gene of A/California/04/
2009 was inserted at EcoRI -Not I sites into pPICK9K
yeast transfer vector under AOX1 promoter in fusion
with S.cervecea alpha secretory signal at N-terminus.
The resultant pPICK9KH1N1HA (Figure 1A), linearized
with Sal I restriction enzyme after transformation in P.
pastoris via electroporation yielded 365 His+ transfor-
mants per 10μg of DNA used. Further selection of all
transformants on Geneticin containing YPD plates
resulted in 145 colonies showing resistance to different
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Page 2 of 13concentrations of Geneticin tested. Eighty one colonies
appeared on the plate containing 250μg/ml Geneticin.
Whereas the selection plates with 500μg/ml and 750μg/
ml Geneticin had 43 and 21 colonies respectively. Geno-
mic DNA PCR from twenty selected yeast transformants
using AOX 1 forward and HA gene specific reverse pri-
mer resulted in amplification of approximately 1.96 kb
products as expected. Fourteen out of twenty DNA sam-
ples amplified the expected 1.96 kb DNA along with
known positive control, whereas, DNA from non recom-
binants did not show any amplification (Data not
shown). Multiple copy integrants having more than four
copies of HA gene were selected based on antibiotic
s e n s i t i v i t ya s s a ya n dG e n o m i cD N AP C R .T h ec l o n e s
that were resistant to higher concentrations of Geneticin
also showed intensive bands in genomic DNA PCR and
these results were in agreement with that of Geneticin
sensitivity assay.
Optimisation of expression parameters and purification of
soluble glycosylated HA0 protein from yeast culture
supernatant
We have employed S. cerevisiae a-mating factor pre-pro
leader sequence secretory signal (SS) upstream to the
HA gene in the pPICK9KH1N1HA construct. This sig-
nal sequence comprises a 19 amino acid signal peptide
(pre-sequence), followed by a 60 amino acid pro-region.
The endopeptidase and kex2 protease of Pichia cleaves
the Pre and Pro fusion fragments of the expressed pro-
tein respectively, resulting in the release of the matured,
fully processed HA protein. All the fourteen His+ Mut+
colonies that were found positive through PCR were
selected for inducing the expression of the target gene.
Out of fourteen clones induced, two clones showed bet-
ter expression of the HA recombinant protein of size
~80 KDa after 46 hr induction. Whereas no specific
protein bands were detected in pPICK9K vector trans-
formed yeast and un-induced positive transformants in
this region. Studies conducted to scale-up the expression
level with different induction period and methanol con-
centrations revealed that 46 hr of post-induction with
2% methanol concentration is optimum for better
expression of H1N1 HA protein in shaker flask culture
level (Data not shown). Upon quantification, the con-
centration of the HA protein expressed was found to be
60 mg/Lt of the culture supernatant. However, the level
of expression could not be further elevated above this
scale with either increased methanol concentration or
increased duration of incubation. With the above opti-
mised expression conditions,p r o p e r l yf o l d e dg l y c o s y -
lated HA0 was secreted into the medium as soluble
protein. The expressed HA0 protein ran as a single
band on SDS-PAGE with the anticipated molecular
weight of approximately 80 KDa (Figure 2A). No signifi-
cant trimers or dimeric forms of the HA protein were
detected on the gel under denaturing conditions. How-
ever, high molecular weight protein corresponding to
the trimeric form of HA (~240 KDa) was noticed along
with HA0 monomers under native conditions (Figure
2B).
FPLC size exclusion chromatography purification of
the expressed native protein revealed a broad major
peak corresponding to a known protein of molecular
weight of ~80 KDa that correlated with that of the
intact HA0 protein. The peaks corresponding to the HA
timers also formed a narrow intense peak that was
further confirmed via immunoblotting (Figure 3). Minor
peaks corresponding to the breakdown products of HA0
into HA1/HA2 were also observed. However the con-
centration of these breakdown products were
Figure 1 Vector map of the recombinant construct and Schematic diagram of genetic recombination in Pichia. Panel 1A: Plasmid map
of recombinant yeast transfer vector pPIC9KH1N1HA. Panel 1B: Schematic diagram showing the genetic recombination event that result in the
formation of Pichia transformant with multiple-copy integrants(The gene of interest (H1N1HA) is positioned between Eco RI and Not I sites under
the control of AOX1 promoter, the secretory signal (SS), transcription termination (TT) signal sequences are on 5’ and 3’end of the H1N1HA gene
respectively. HIS 4 locus is carrying the Sal I recognition sequence and the integration of the transgene within the Pichia genome will be at His
4 locus).
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Page 3 of 13significantly very less in comparison to the intact HA0
as also seen on the native Coomassie stained gel (Figure
2B).
Western blot analysis of the yeast expressed protein
The recombinant protein obtained from positive Pichia
transformants after methanol induction were separated
on PAGE gel under both denaturing and native condi-
tions were subsequently transferred onto PVDF mem-
branes. Western blotting using H1N1 HA specific
polyclonal antibodies confirmed the authenticity of the
expressed proteins. Appropriate positive signals were
obtained only in case of the culture supernatants of
positive yeast transformants, whereas the protein sample
transferred from Pichia transformed with pPICK9K
negative control did not develop any signal on the mem-
brane. HA0 monomers and HA trimers were recognised
by the H1N1 HA specific antibodies used in the present
study both under denaturing and native conditions
respectively (Figure 4A and 4B).
Trypsin cleavage analysis of yeast derived H1N1 HA0
recombinant protein
Upon trypsin digestion, the expressed HA0 showed clea-
vage into HA1 (55-60 KD) and HA2 (40-45 KD) as seen
on native PAGE (Figure 5, lane 1). Whereas in case of
mock digested HA protein, no such fragments were
noticed (Figure 5, lane 2).
Immunization of mice and rabbits with yeast derived
H1N1HA recombinant protein
To evaluate the elicitation of neutralising antibodies
against the yeast expressed Hemagglutinin recombinant
protein, BALB/c mice and rabbits were immunised
intramuscularly after mixing with Freund’sc o m p l e t e
adjuvant. An average antibody titre of 1:512 was
observed in case of mice group immunised with 50μgo f
HA after two weeks of immunization, whereas, the mice
group that received 10μg of HA had an antibody titre of
Figure 3 FPLC purification of yeast derived HA protein via size
exclusion chromatography.
Figure 2 PAGE analysis of the culture supernatants under
denaturing and native conditions demonstrating the secreted
expression of recombinant HA protein as HA monomers and
HA trimers respectively. Panel 2A: Methanol induced culture
supernatants under denaturing conditionLane M: Pre-stained Protein
marker (Fermentas, USA, #SM 0671) Lane 1: Cell culture supernatant
from Pichia multiple copy integrant Clone A Lane 2: Cell culture
supernatant from Pichia multiple copy integrant Clone B Lane 3:
Cell culture supernatant from Negative clone Panel 2B: Methanol
induced culture supernatants under native conditionLane M: Pre-
stained Protein marker (Fermentas, USA, #SM 1811) Lane 1: Cell
culture supernatant from Pichia multiple copy integrant Clone B
Lane 2: Cell culture supernatant from Pichia multiple copy integrant
Clone A Lane 3: Cell culture supernatant from Negative clone.
Figure 4 Western Blot analysis of the culture using H1N1 HA
specific antibodies confirming the secreted expression of
recombinant HA protein supernatants under denaturing and
native conditions. Panel 4A: Under denaturing condition: Lane M:
Pre-stained Protein marker (Fermentas, USA, #SM 0671) Lane 1: Cell
culture supernatant from Pichia multiple copy integrant Clone A
Lane 2: Cell culture supernatant from Pichia multiple copy integrant
Clone B Lane 3: Cell culture supernatant from negative clone Panel
4B: Under native condition: Lane M: Pre-stained Protein marker
(Fermentas, USA, #SM 0671) Lane 1: Cell culture supernatant from
Pichia multiple copy integrant Clone A Lane 2: Cell culture
supernatant from Pichia multiple copy integrant Clone B Lane 3:
Cell culture supernatant from negative clone.
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Page 4 of 131:256. Interestingly both the immunised rabbits showed
better seroconversion as early as two weeks of immuni-
zation with an antibody titre of 1:2048 when compared
to the control non immunised animal. Following two
weeks of booster, the antibody titres shot up to 1:2048
and 1:1024 in case of mice group immunised with 50 μg
and 10 μg of HA respectively. Both the immunised rab-
bits had an antibody titre of 1:8192 (table 1) after two
weeks of booster injection.
Hemagglutination Inhibition (HI) activity of H1N1HA
immunised mice and rabbit sera
The HI assay is the most widely accepted serological
test for influenza immunity and is the gold standard
measure of functional HA-specific antibodies after vacci-
nation. The MDCK derived H1N1 virus agglutinated
c h i c k e nR B C su pt o1 : 8d i l u t i o n sa n dh e n c et h i sw a s
considered as 1HA unit (Figure 6A). After two weeks of
initial immunization, HI titres were induced in both
immunised mice groups and rabbits with mean HI titres
reaching about 1:32 (Figure 6B). After two weeks of
booster injection, the HI titres remained same in both
immunised mice groups. Whereas the rabbits showed an
elevated titres of 1:64 (table 1).
Invitro neutralisation activity of H1N1HA immunised mice
and rabbit sera (Plaque Reduction Neutralisation Test)
Plaque Reduction Neutralisation Test (PRNT) was per-
formed on the sera samples collected after two weeks of
booster immunisation both in case of mice and rabbits.
The serially diluted sera were challenged with 100 pfu
showed 50% reduction in plaque numbers up to 1:256
dilutions in case of mice group that received 50μgo f
HA protein. However, the mice group that were immu-
nised with 10μg of HA protein had more than 50%
reduction in plaque numbers only up to 1:64 dilution.
T h ei m m u n i s e dr a b b i ts e r aa l s os h o w e dan e u t r a l i z i n g
titres of 1:256 up to which there was 50% reduction in
the plaque numbers (Figure 7, panel A). Whereas, the
sera from the control mice group and rabbit did not
show any significant reduction in the plaque numbers at
any of the dilutions tested (Figure 7, panel B). Figure 7
(panel C) depicts the different PRNT titres obtained
with each animal group.
Discussion
Pichia pastoris has been used successfully to express a
wide range of heterologous proteins [12,24,26,
32-36,41,42]. Heterologous expression in P. pastoris can
Figure 6 Hemagglutination (HA) activity of H1N1 virus and Hemagglutination Inhibition (HI) activity of HA immunized sera using
chicken RBCs.Panel 6A: Hemagglutination (HA) activity of H1N1 virus. Lane A: Two fold serial diluted MDCK derived H1N1 virus mixed with
0.5% chicken RBCs. Lane B: Negative control (PBS mixed with 0.5% chicken RBCs). Panel 6B: Hemagglutination Inhibition (HI) activity of HA
immunized sera using chicken RBCs. Lane A: Negative control (None immunized mice serum mixed with 4HA units of H1N1) Lane B: Two fold
serially diluted HA immunized representative mice serum mixed with 4HA units of H1N1 Lane C: Two fold serially diluted HA immunized
representative rabbit serum mixed with 4HA units of H1N1.
Figure 5 Native PAGE analysis of the yeast derived H1N1HA
digested with trypsin Lane M: Pre-stained Protein marker
(Fermentas, USA, #SM 0671) Lane 1: Recombinant H1N1HA after
digestion with trypsin Lane 2: Negative control (Recombinant
H1N1HA mock digested).
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Page 5 of 13Figure 7 Plaque Reduction Neutralization Test (PRNT) of HA immunized sera demonstrating virus neutralization activity against H1N1
virus. Panel 7A and 7B: Representative immunized rabbit serum showing virus neutralisation activity against H1N1 virus (panel A) compared to
the non immunised control rabbit serum (panel B) Panel 7C:Graph depicting the PRNT titres (50% plaque reduction) of immune mice/rabbit sera
samples in comparison to non immune sera samples.
Table 1 Concise summary of the Immunization study of yeast derived HA protein in mice and rabbits
Animal group Sera sample Antibody titre HI titre
# PRNT titre
#
Mice group V1
(50μg/dose/animal)
Pre Immune <1:16 0 <16
2 wks post Immunisation 1:512 32 NT*
2 wks post booster 1:2048 32 256
Mice group V2
(10μg/dose/animal)
Pre Immune <1:16 0 <16
2 wks post Immunisation 1:256 32 NT*
2 wks post booster 1:1024 32 64
Mice control group Pre Immune <1:16 0 <16
2 wks post Immunisation <1:16 0 NT*
2 wks post booster <1:16 0 <16
Rabbit 1 (50μg/dose/animal) Pre Immune <1:16 0 <16
2 wks post Immunisation 1:2048 32 NT*
2 wks post booster 1:8192 64 256
Rabbit 2 (50μg/dose/animal) Pre Immune <1:16 0 <16
2 wks post Immunisation 1:2048 32 NT*
2 wks post booster 1:8192 64 256
Rabbit Control Pre Immune <1:16 0 <16
2 wks post Immunisation <1:16 0 NT*
2 wks post booster <1:16 0 <16
NT* - Not tested; # HI and PRNT titres are the mean reciprocals obtained against the H1N1 virus isolated during the 2009 outbreak in India
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Page 6 of 13be either intracellular or secreted. The major advantage
of expressing heterologous proteins as secreted protein
is that Pichia pastoris secretes very low levels of native
proteins. That combined with the very low amount of
p r o t e i ni nt h em i n i m a lPichia growth medium, means
that the secreted heterologous protein comprises the
vast majority of the total protein in the medium and
serves as the first step in purification of the protein [43].
I nt h ep r e s e n ts t u d yw eh a v eg e n e r a t e dr e c o m b i n a n t
Pichia clones in which multiple copies of H1N1 HA
transgene are integrated. The recombinant HA protein
is also separated from secretory signal by the action of
host specific endopeptidase resulting in the release of
the matured, fully processed HA protein. Unlike bacteria
the transgene in case of yeast is integrated within the
genome, hence it is difficult to lose the target gene
when the recombinant yeast is cultured and passaged
several times. A further advantage of selecting for multi-
copy transformants is that if there is a mutation in one
particular copy of the expression cassette, arising from
the integration process, then the protein that results
from this mutant copy may not contribute as signifi-
cantly to the total amount of protein expressed. In case
of native Influenza virus, the monomers of HA folds to
form a membrane proximal stalk and a membrane distal
globular head domain. The globular head stands inde-
pendently from the central stalk and contains the major-
ity of the neutralizing antibody epitopes and the HA
monomers are oligomerised into HA trimers [44,45].
Hence in order to have a neutralising immune response
from protein based vaccine, HA in its native form may
be the best target. The full length and partial H1N1 HA
protein has been previously expressed in bacterial sys-
tem [46]. There is a report on lower level of expression
of Human Influenza A/WSN/33 HA protein in S. cerevi-
siae [47]. However this reported protein is truncated,
hyperglycosylated and is also cell-associated and have
not demonstrated its in vivo applications. Xavier Saelens
et al have successfully expressed the H3N2 HA protein
in Pichia pastoris as a soluble secretory protein in its
monomeric form but not as trimeric form [48]. However
they have also have demonstrated protective efficacy of
the monomeric H3N2 HA in mice model. But there are
no reports on the expression of pandemic H1N1 viral
protein using Pichia pastoris expression host so far.
Here we demonstrate that that P.pastoris is capable of
expressing a soluble form of H1N1 HA with near native
antigenic structure in trimeric form. Furthermore, the
yeast derived recombinant HA is also capable of eliciting
ag o o dn e u t r a l i s i n ga n t i b o d yr e s p o n s ei nm i c ea n d
rabbits.
From the current study it is evident that in order to
have a good expression of full length H1N1 HA gene,
multiple copy integrants carrying more than 4 copies of
the target gene are essential. The mixture of trimers and
monomers observed in the present study could be
attributed to the influence of extracellular pH. This is in
accordance with the previous report wherein the extra
cellular pH has influenced the trimerization and trans-
port of HA from the mammalian host cells [49]. Even
though the pH of the induction medium was initially
adjusted to 8.2, at the time of protein harvest, drop in
pH to acidic range (pH 6-7) was noticed which probably
would play a role in inhibiting the oligomerization of
the secreted HA monomers. As it was shaker flask cul-
ture, it was practically difficult to continuously monitor
the extra-cellular pH and in addition it seems unlikely
that if there is any trimerization of HA happening
within the yeast cell, the aggregated HA trimers of high
molecular weight could traverse the yeast cell wall. In
order to have correctly folded glycosylated protein, full
length HA synthetic gene was used in the present study
for expression in yeast. Out of several clones screened,
two clones carrying multiple copies of HA gene showed
better expression of the target protein, whereas the
other clones had weak expression of the target protein.
This observed reduced expression level may be attribu-
ted to the low copy number of the transgene integrated
within the yeast genome. This is in agreement with the
earlier reports wherein multi-copy recombinants or the
jackpot clones increases the expression levels of the tar-
get protein due to more number of copies or gene
dosage [31,33]. SDS-PAGE and Western blotting analy-
sis revealed the expression of a specific protein, whose
molecular weight was approximately 80 KDa from
recombinant P. pastoris a n dt h i se x p r e s s e dp r o t e i n
reacted with H1N1 HA specific antibodies. The Mono-
mers of the expressed HA also formed trimers similar
to the HA trimers on the native virus. The trimeric HA
was of higher molecular weight of approximately 240
KDa as seen on the native PAGE. These trimeric HA
proteins under denaturing conditions, got dissociated
into its constituent monomers. The H1N1 HA specific
antibodies used in the present study also have confirmed
the authenticity of the HA trimers. It is noteworthy to
mention that the HA gene expression was noticed up to
five passages during the course of this study indicating
good genetic stability of the introduced HA gene within
the recombinant yeast system.
During optimisation, all though different harvest time
points were tested, the protein bands were clearly visible
only in case of the samples that were incubated for 46
hr of post methanol induction and band intensities were
s i g n i f i c a n t l yr e d u c e di nt h et i m ep o i n t sc o l l e c t e db e f o r e
46 hr of post induction. Prolonged incubation after 46
hrs up to 96 hrs post induction resulted in the break-
down of the target protein. Very faint but multiple
bands were observed following 72 hr and no bands were
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Page 7 of 13visible after 96 hr of incubation indicating that host-spe-
cific proteases may be acting on the protein following
prolonged incubation. These findings clearly suggest
that early harvesting of the culture supernatant is neces-
sary to have an intact H1N1 HA protein without any
proteolytic damage. In addition to the earlier discussion
on the influence of pH for obtaining HA trimers, pH of
the medium also played a critical role in the stability
and integrity of the HA protein expressed extra-cellu-
l a r y .I tw a so b s e r v e dt h a tt h ea c i d i cp Hi sn o ts u i t a b l e
for the stability of the expressed protein. Rather slightly
a l k a l i n ep H( 8 . 2 )s h o w e dv e r yg o o ds t a b i l i t yo ft h e
expressed recombinant HA protein. As Pichia cells are
better adapted for growth under acidic environment, the
increased pH of the medium had some adverse effects
on the biomass. The culture was also harvested at an
early stage (46 hrs), this would be another reasons for
not getting a high cell density using shaker flask culture.
Another important parameter for efficient expression of
HA in Pichia was adequate aeration during methanol
induction. Hence the culture volume of the flask was
kept as low as 10% of the total flask volume. It was also
necessary to maintain the incubation temperature at 28°
C with rotation of 250 rpm. Under optimal condition,
the expressed protein amounted to be about 60 mg/Lt
of the culture in shaker flask condition. As this yield
obtained was under normal shaker culture conditions, it
should be possible to obtain several fold higher expres-
sion levels by optimized fermentation procedures, allow-
ing cell densities of A600 = 200 ± 400 instead of 5 ±10.
Yeast expression system like S. cerevisiae can hyper
glycosylate the recombinant protein with high mannose-
type oligosaccharides and hence the recombinant pro-
tein can be recognized by mannose receptors when
injected into mammalian species [50-52]. S. cerevisiae
glycosylation has terminal a-1, 3 linked mannose resi-
dues and it is this residue that is thought to be anti-
genic. Whereas P. pastoris does not have this terminal
link [50,53] and hence is a better system for recombi-
nant antigen expression. H1N1 HA derived from yeast
in the present study was found to be less immunogenic
but efficacious in eliciting good neutralising immune
response in mouse model. From the Coomassie stained
gels, it is evident that majority of the protein secreted
into the medium was the HA protein with negligible
amount of non specific host proteins. Hence this study
is very significant for easy and economical downstream
processing of the recombinant protein.
From the preliminary immunisation experiments con-
ducted, it is evident that mice receiving the recombinant
HA as low as 10μgw e r ea b l et oi n d u c ean e u t r a l i s i n g
antibody titre of 1:64. Whereas both mice and rabbits
that received 50μg of recombinant protein had a neutra-
lising antibody titre of upto 1:256. However the present
studies in animal models are in proof of concept stage
wherein the yeast derived recombinant H1N1 HA pro-
tein has been demonstrated to elicit virus neutralizing
antibodies. Appropriately designed biological challenge
experiments with various concentrations of the recombi-
nant protein in combination with different types of adju-
vants and comparative studies with the commercially
available vaccines are in progress. Previous studies [8]
have demonstrated micro-neutralisation titres of 1:160
in ferrets. Thus the micro neutralisation titre obtained
in the present study is quite encouraging and probably
sufficient enough to provide complete protection against
the lethal virus challenge.
The H1N1 Hemagglutinin protein is known to carry
neutralizing epitopes, hence the yeast derived glycosy-
lated HA protein obtained from our study may find dual
applications in both disease diagnostics and prophylaxis.
As the main objective of the present study was confined
to the recombinant expression of H1N1 HA using P.
pastoris, detailed studies pertaining to the prophylaxis
and diagnostic potential of this recombinant protein
were beyond the scope of this study at this stage. How-
ever in another study we have initiated evaluating the
diagnostic potential of the yeast derived HA protein
either in detecting H1N1 specific antibodies in human
serum samples or in direct detection of H1N1 virus in
clinical samples employing chicken polyclonal antibodies
raised against the recombinant HA protein. The key
benefits of using yeast for expressing H1N1 HA protein
are that the recombinant protein can be made quickly,
inexpensively and in quantities sufficient to meet global
needs. The efficiency of this technology translates sev-
eral fold increase in production. As a point of reference,
the average yield for cell culture is 3 mg/Lt; for egg
based production, 7 mg/Lt; for baculovirus recombinant
synthetic protein, 13 mg/Lt [45]. Whereas for the stan-
dard yeast system described here we could able to reach
an yield of 60 mg/L using shaker flask culture and this
yield can be certainly elevated further using fed batch
fermentation. This increase in production capacity,
along with the fact that it is carried out in a yeast sys-
tem, provides an opportunity to address several short-
comings of the current egg-based system. One
advantage deriving from increased capacity is the ability
to increase the dose of antigen. Formulation of a ‘’high-
dose’’ vaccine for the elderly becomes a practical possi-
bility with an unconstrained supply of antigen. A second
set of advantages comes from eliminating the growth of
virus from the manufacturing process.
Conclusion
We have successfully expressed the trimeric hemaggluti-
nin protein of H1N1 using yeast system (Pichia pastoris)
in secreted form. The yeast derived HA protein is
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mice and rabbit models. The sera from immunised ani-
mals also exhibited Hemagglutination Inhibition (HI)
activity. Hence Pichia pastoris m a yb ec o n s i d e r e da sa n
appropriate alternate for the development of an easily
adaptable, safe and economic alternative HA based sub-
unit vaccine. Although the mouse model used here is
commonly accepted to evaluate experimental influenza
vaccines, the results described should only be regarded
as initial proof of principle. The manufacturing
approach described here can be further scaled up to
high levels of productivity and the flexibility and poten-
tial speed associated with yeast expression system may
prove to be indispensable during pandemic influenza
outbreak.
Materials and methods
Yeast strain and growth conditions
P. pastoris GS115 (Invitrogen, USA) was grown at 28°C
in YPD medium (Yeast Extract Peptone Dextrose Med-
ium). For growth on plates, 2% agar was added to the
media. Transformants were grown in media supplemen-
ted with 250-750 μg/ml Geneticin (Sigma, USA). For
cloning procedures, Escherichia coli DH5 a were used
and grown at 37°C in LB medium supplemented with
50 μg/ml either kanamycin or ampicillin.
DNA techniques
Molecular biology protocols were carried out according
to Sambrook and Russell [21]. E. coli and P. pastoris
cells were transformed by Electroporation. Enzymes Eco
RI, Not I, Sal I and T4 DNA ligase (Fermentas, USA),
Taq DNA polymerase and reagents for PCR (Invitrogen,
USA) were used as recommended by the supplier. DNA
sequencing was performed by ABI DNA sequencer
(Applied Biosystems, USA). DNA sequences were ana-
lyzed using DNA star software.
Cloning H1N1 HA gene into pPICK9K yeast transfer vector
The DNA corresponding to nucleic acids 1 to 1699 of
the HA gene from novel California/04/2009 H1N1
[Genbank:FJ966082.1] was synthesized by Biotech desk
(Hyderabad, India). The full length HA-encoding syn-
thetic gene was PCR amplified from the synthetic con-
struct using high fidelity Pfu Taq polymerase
(Fermentas, USA) employing the following primers hav-
ing introduced Eco RI and Not I sites in the forward
and reverse primers respectively. H1N1HA Forward: 5’-
TTG GAT CCA GAA TTC ATG AAG GCA ATA
CTA GTA GTT CTG-3’ [Base pairs: +1 to +24 Gen-
bank: FJ966082.1]; H1N1HA reverse: 5’-TGG ATC CGC
GGC CGC A A TA C AT A TT C TA C AC T GT A G
AGA -3’ (Base pairs: +1699 to +1681 NCBI Genbank:
FJ966082.1]. The PCR conditions used were: 94°C for 45
sec, 63°C for 45 sec, 72°C for 1 min and 30 sec, for 35
cycles, and finally 72°C for 10 min. The amplified HA
gene was digested with Eco RI and Not I restriction
enzymes and was cloned into pPIC9K yeast transfer vec-
tor (Invitrogen, USA) at the same restriction sites. The
resulting vector pPICK9KH1N1HA (Figure 1) had the
HA gene in frame with the fused Saccharomyces cerevi-
siae a-mating factor secretion signal under control of
the methanol-inducible P. pastoris alcohol oxidase 1
(AOX1) promoter. [The complete sequence of the resul-
tant pPIK9KH1N1HA recombinant construct is sub-
mitted to NCBI Genbank: HQ398363.1]. The
pPICK9KH1N1HA DNA was transformed into E.coli
DH5 alpha strain (Invitrogen, USA) via heat shock
method. For selection of the recombinant transformants,
the bacterial cells were cultured in Luria-Bertani med-
ium (Himedia, India) supplemented with 50μg/ml ampi-
cillin and 50 ug/ml of Kanamycin. The positive bacterial
transformants were selected through restriction diges-
tion of plasmid DNA using Eco RI and Not Ie n z y m e s
and PCR analysis using alpha factor forward (5’-T A C
TAT TGC CAG CAT TGC TGC-3’) and H1N1 HA
reverse primers. Correct integration will result in the
formation of a 1.96 Kbp PCR product. The complete
HA gene sequence was further confirmed through
nucleotide sequencing using ABI sequencer for any pos-
sible mutations introduced during PCR step.
Integration of pPICK9KH1N1HA DNA into Pichia pastoris
genome and screening of the transformants
The recombinant plasmid DNA pPIC9KH1N1HA was
linearized by digesting with Sal I enzyme to integrate
the transgene at His4 locus on the Pichia genome and
also to generate HIS+, Mut+ transformants in Pichia
pastoris GS115 cells. Ten microgram of the linier DNA
was used to transform fresh electro competent P. pas-
toris cells via electroporation using Bio-Rad Gene Pulsar
Xcell™ electroporation system (Bio-Rad laboratories,
Inc USA.) at three different voltages (1600V, 1800V and
2000V), 20μF capacitance and 200Ω resistance. After
transformation, cells were plated on SD-His plates
(1.34% yeast nitrogen base, 2% dextrose, 0.01% complete
amino acid supplement minus Histidine, 1 M sorbitol
supplement, and 2% agar), and incubated at 30°C for 2
days. The parent pPIC9K without insert, linearized with
Sal I was also transformed similarly for negative control.
The colonies obtained were streaked on fresh SD-His
plates. It is often desirable to select for transformants
containing multiple integration events (Figure 1B) as
such clones potentially express significantly higher levels
of the recombinant protein. Three hundred and sixty
five transformed colonies bearing the chromosomally
integrated copies of the pPICK9KH1N1HA were
screened for single, double or multiple copy integrants
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ent concentrations of Geneticin (250μg, 500μga n d
750μg). Plates were incubated at 30°C for four days and
the growth obtained was scored with plus (+) and
minus (-) for the presence or absence of growth respec-
tively on the selection plate. Since both Kan
R and
H1N1HA gene are integrated together, resistance to
Geneticin would indicate the copy number of the inte-
grated H1N1 HA gene. As a reference, clones that grow
well on selection plate with Geneticin concentration of
250μg/ml, 500μg/ml and 750μg/ml were considered to
have single, double and more than four copies inte-
grated respectively. To further confirm the transfor-
mants having multiple copy integrants, PCR was
performed on the genomic DNA isolated from selected
colonies by employing alpha factor secretary signal for-
ward and H1N1HA reverse primers. A total of twenty
clones were randomly picked up from all the three cate-
gories (3, 6 and 11 clones each from 250μg/ml, 500μg/
ml and 750μg/ml plates respectively) and were inocu-
lated into 10 ml of YPD broth and grown at 28°C until
the OD was 2-3. The OD in all was finally adjusted to 2
using the blank YPD medium and 10 ml of each culture
was further used for Genomic DNA extraction. The
template DNA concentrations in all cases were equally
adjusted in the PCR reactions to check its sensitivity to
screen single, double and multiple copy integrants along
with appropriate control as reported earlier [41]. Four-
teen PCR positive Pichia clones that were found to con-
tain single, double and more than four copies of the
H1N1HA gene integrated were selected further for sub-
sequent expression studies.
Expression analysis and optimization of H1N1 HA protein
expression in Pichia system
Fourteen PCR positive His+ Mut+ Pichia clones were
selected for methanol induction. The glycerol stocks of
the above Pichia clones were inoculated separately into
50-ml of either YPGy (1%Yeast extract, 2%bacto peptone
and 1%glycerol buffered with 100 mM potassium phos-
phate buffer, pH 8.2) or Buffered Minimal Glycerol
medium-BMGM (100 mM potassium phosphate, pH
8.2, 1.34% YNB, 4 × 10
-5 % biotin, 1% Glycerol) taken in
500 ml conical flask along with negative control (Pichia
transformed with pPICK9K without insert) and were
incubated at 28°C in a shaker incubator at 250 rpm
until the culture reached an A600 of 4-5. The cells were
harvested by centrifugation at 3,000 × g for 10 min at
room temperature and the cell pellets were resuspended
in required volume of either fresh YPM induction media
(1%Yeast extract, 2%bacto peptone and 0.5 - 2.5%
Methanol, buffered with 100 mM potassium phosphate
buffer, pH 8.2) or Buffered Minimal Methanol medium-
BMM (100 mM potassium phosphate, pH 8.2, 1.34%
YNB, 4 × 10
-5 % biotin, 0.5%- 2.5% methanol) so as to
get an A600 of 3 in all. Several methanol concentrations
ranging from 0.5 to 2.5% (0.5%, 1%, 1.5%, 2% and 2.5%)
were tried in both media in order to choose the opti-
mum concentration of methanol for induction in case of
shaker flask culture. Incubation was continued at 29°C
on an orbitary shaker (250 r p m )f o rf o u rd a y s .T os u s -
tain induction, required volume of methanol was added
to every flask once in every 24 hour. Culture superna-
tants were collected at different time points ranging
from 16-96 h (16 h, 23 h, 46 h, 72 h and 96 h) and
were concentrated to 1/10 of its original volume using
cellulose membrane with a pore diameter of 10 KDa
(Millipore Corporation, USA) by centrifuging at 4000 g
for 10-20 min at 4°C. Protease inhibitor cocktail
(Amersco, USA) was added to the concentrated samples
and the samples were stored at -80°C until all the time
points were collected. Two clones with multiple copy
integrants (Showing Geneticin resistance up to 750μg/
ml and also resulted in intensive HA amplified PCR pro-
duct) showing high expression of a recombinant protein
were further selected for subsequent optimization
experiments. The expression conditions viz methanol
concentration (0.5-2.5%), type of medium (YPGy or
BMGM), pH of the medium (6 - 8.5) and the time of
harvest (16 h, 23 h, 46 h, 72 h and 96 h) were tested in
order to get the intact HA protein expressed in abun-
dance without any host specific proteolytic cleavage.
The final protein obtained after optimization of the
expression conditions obtained from cell culture super-
natants were determined through Bradford assay against
BSA standards [54]. The protein samples were further
analyzed by running them on 10% polyacrylamide gel
electrophoresis (PAGE) both under denaturing and
native conditions [21]. The gels were subsequently
stained with Coomassie Brilliant Blue R-250 (Sigma,
USA). The expressed HA protein was confirmed
through western blotting using rabbit anti H1N1 HA
specific polyclonal antibodies (Genscript, USA) and goat
anti rabbit alkaline phosphatase conjugated IgG (Sigma,
USA) as primary and secondary antibodies respectively.
The colour development was done either using BCIP/
NBT solution (Sigma,USA) or H2O2/DAB substrate/
chromogen (Sigma,USA).
Concentration of HA protein
The culture supernatants showing high level of secreted
expression under optimal expression conditions were
collected after methanol induction. The protein were
concentrated ten times using 10 KD MWCO spin col-
umns (Millipore,USA) by centrifuging at 4000 g for 20-
30 min at 4°C.
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on size exclusion principle
The Yeast expressed protein recovered from the yeast
culture supernatant was subjected to fast protein liquid
chromatography (FPLC) using Akta explorer (Amer-
sham, USA) employing previously equilibrated (in two
column volumes of 20 mM Phosphate Buffered Saline,
pH 7.2) Superdex 200 10/300 column (GE-Healthcare,
USA). The Hemagglutinin protein of concentration 3
mg/ml diluted in 2.5 ml of Phosphate Buffered Saline
(pH 7.0) was injected into the size exclusion chromato-
graphy column and the proteins with different sizes
were eluted by monitoring the protein at 280 nm. The
peaks obtained were compared with the known molecu-
lar weight marker proteins (GE-Healthcare, USA). Frac-
tions corresponding to monomers and trimers of HA
were collected separately for further use.
Analysis of the recombinant HA protein for trypsin
cleavage
The yeast derived HA protein was checked for its clea-
vage into HA1 and HA2 fragments via trypsin digestion.
To 10μg of yeast expressed HA protein, trypsin (100μg/
ml stock made in PBS, pH7.2) was added to a final con-
centration of 1μg/ml and incubated at 37°C for one
hour. The digested HA protein sample along with the
negative control (HA protein undigested with trypsin)
were run on 10% native PAGE and stained with coo-
massie brilliant blue.
Immunization of mice and rabbits with yeast derived
H1N1HA recombinant protein and detection of serum
antibodies through antibody capture ELISA
The animal studies experiments had an approval from
the Institutional Animal Ethics Committee (IAEC) wide
registration number 37/1999/CPCSEA and Institutional
Biosafety committee (IBSC) wide reference no: IBSC/
VIRO-01/05/TNA as per the institutional norms. The
principles of good laboratory animal care were followed
all through the experimental process. Eighteen healthy
BALB/c mice 6-8 week-old were made into three groups
with six animals in each group. The animals were found
to be sero negative for the circulating H1N1 influenza.
Two groups were immunized intramuscularly each with
50μga n d1 0 μg of yeast derived H1N1 HA protein in
Freund’s complete adjuvant (FCA) (Sigma,USA) and the
animals of the control group were immunized with the
expressed product of negative control P. pastoris. Simi-
larly two healthy adult male New Zealand White rabbits
tested sero negative for H1N1 were immunized intra-
muscularly with 50μg each of yeast derived HA protein
in combination with FCA for negative control, one rab-
bit was similarly immunized with FCA alone. After two
weeks, animals were boosted once with the same
amount of protein in combination with Freund’s Incom-
plete adjuvant (FIA) (Sigma, USA). Following two weeks
of the booster dose, blood samples were collected either
from retro-orbital route (In case of mice) or marginal
veins (rabbits) and the sera were separated. Antibody
capture ELISA was performed to determine the antibody
titre against the H1N1HA protein [16]. Briefly, the yeast
expressed H1N1 HA protein was coated overnight onto
Nunc polystyrene microtitre plates (300 ng/well in 0.1
M sodium bicarbonate, pH 8.0) and the non reacted
sites were blocked using 3% BSA. The captured proteins
were reacted first with the immunised mice and rabbit
sera and were subsequently incubated with their respec-
tive anti-species secondary HRP conjugates (Sigma,
USA) for 1 hour. Enzymatic colour development was
done using TMB/H2O2 chromogen/substrate solution.
The samples showing the OD values twice that of nega-
tive serum were considered to positive and were used in
determining the titre of the antibody.
Culturing H1N1 virus and determination of its
Hemagglutination (HA) titre and virus quantification
through Plaque assay
The H1N1 virus isolate from clinical sample in Banga-
lore, India during 2009 outbreak was a kind gift from
Dr.V.Ravi, NIMHANS, Bangalore, India. The H1N1
virus was propagated using Madin Darby Canine Kidney
(MDCK) cell lines as described earlier [45,49]. Hemag-
glutination assay was performed on the H1N1 virus
stock using chicken RBC. Briefly, chicken RBCs were
separated from the whole blood and washed three times
in PBS (pH7.2). Fifty micro litres of 0.5% RBC suspen-
sion (v/v in 1% PBS) was added to 50μl serially diluted
H1N1 influenza virus in U-bottom 96 well plates. The
plates were incubated at room temperature for one hour
and were observed for the formation of button or mat
within the wells.
For quantifying the H1N1 virus, plaque assay was per-
formed by serially diluting the virus stock on MDCK
cells in six well plates. The plaques formed after three
days of post infection were counted and the titre of the
virus stock was determined. The H1N1 virus stock with
known HA titre and virus concentration was used for
subsequent experiments. The culturing of the virus,
determination of Hemagglutination (HA) test and pla-
que assay were performed in Bio safety level 3 (BSL-3)
laboratory.
Hemagglutination Inhibition (HI) activity of H1N1HA
immunised mice and rabbit sera
Two fold dilutions of immunised/control mice and rab-
b i ts e r aw e r em a d ei nU - b o t t o m9 6 - w e l lm i c r ot i t r e
plate. Four Hemagglutination units (HAU) of influenza
virus were added in each well and the virus-serum
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sion of chicken RBC (in PBS pH7.2) were added and
mixed by agitation. The chicken RBCs were allowed to
settle for one hour at room temperature and HI titres
were determined by the reciprocal value of the last dilu-
tion of the sera which completely inhibited the Hemag-
glutination of chicken RBCs.
In-vitro neutralisation activity of H1N1HA immunised mice
and rabbit sera
Serum samples were heat-inactivated at 56°C for 30 min-
utes. Two-fold serial dilutions from 1:16 to 1:1024 were
prepared in virus diluent (MEM with L-glutamine) con-
taining no serum or antibiotic/antimycotic solution. Seri-
ally diluted serum was challenged with an equal volume
o ft h eH 1 N 1v i r u s ,p r e v i o u s l yt i t r a t e dt og i v e1 0 0p f ui n
250 μl of virus dilution. The virus control of the experi-
ment contained the virus diluted in the virus diluents
without serum. The serum/virus mixtures were incubated
at 37°C, 5% CO2 for one hour. MDCK cell monolayers,
prepared in six well plates were infected with 500 μl/well
of the serum/virus mixture. Plates were incubated at
room temperature for one hour. The supernatants were
completely aspirated out from the wells and the wells
were overlaid with 1.5% low melting point agarose
(Sigma,USA) prepared in 2X MEM containing 5 μg/ml
trypsin. Plates were incubated for plaque formation at 37°
C, 5% CO2 for 3 days and the wells were stained with
0.2% crystal violet solution (made in 30% ethyl alcohol).
The plaques formed were counted and neutralisation
activity of the immune sera was assessed by comparing
the plaque numbers obtained from that of negative con-
trol serum. The highest dilution of the sera that showed
more than 50% reduction in plaque number than that of
negative control is considered as the neutralising titre.
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